Inotiv Files for Chapter 11 Bankruptcy

Inotiv Inc. (NASDAQ: NOTV) on June 3, 2026 filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware, the company said in an 8-K filed with the SEC.

The filing discloses entry into a material definitive restructuring support agreement with certain lenders and other parties, per Item 1.01 of the Form 8-K. It also reports a bankruptcy filing under Item 1.03, triggering events that accelerate or increase a financial obligation under Item 2.04, Regulation FD disclosure under Item 7.01, and other events under Item 8.01.

Inotiv provides nonclinical and analytical drug development services to the pharmaceutical, medical device and veterinary industries. The company did not disclose the exact amount of debt subject to acceleration in the filing.

The Chapter 11 petition immediately places the company under court supervision. Operations continue during the case, but major transactions require bankruptcy court approval. The restructuring support agreement outlines the terms of a planned reorganization that must be approved by the court and creditors.

Downstream, the company must file schedules of assets and liabilities, statements of financial affairs, and monthly operating reports with the court. Creditors will be required to file proofs of claim by a bar date set by the judge. The acceleration clause in the existing credit agreement now requires immediate repayment or renegotiation within the Chapter 11 framework.

Separate motions for debtor-in-possession financing, cash collateral use, and payment of critical vendors are expected to follow in the coming days or weeks.

This is Inotiv's first Chapter 11 filing. The company last reported its financial position in its quarterly report for the period ended March 31, 2026. The bankruptcy case will be assigned to a judge in the District of Delaware, which handles a large volume of corporate reorganizations under standardized local procedures.

The full filing, including exhibits containing the restructuring support agreement, appears as Exhibit 99.1 and related documents in the SEC accession 0001104659-26-069950.